Cargando…

Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study

BACKGROUND: ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Júnior, José Alfreu Soares, Martinho, Glaucia Helena, Macedo, Antonio Vaz de, Verçosa, Marisa Ribeiro, Nobre, Vandack, Teixeira, Gustavo Machado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371230/
https://www.ncbi.nlm.nih.gov/pubmed/30793098
http://dx.doi.org/10.1016/j.htct.2018.05.007
_version_ 1783394531514777600
author Júnior, José Alfreu Soares
Martinho, Glaucia Helena
Macedo, Antonio Vaz de
Verçosa, Marisa Ribeiro
Nobre, Vandack
Teixeira, Gustavo Machado
author_facet Júnior, José Alfreu Soares
Martinho, Glaucia Helena
Macedo, Antonio Vaz de
Verçosa, Marisa Ribeiro
Nobre, Vandack
Teixeira, Gustavo Machado
author_sort Júnior, José Alfreu Soares
collection PubMed
description BACKGROUND: ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment. METHODS: This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Patients receiving umbilical cord blood as the stem cell source were excluded from this analysis. The impact of ABO incompatibility was evaluated in respect to overall survival, event-free survival, transplant-related mortality, acute graft-versus-host disease and engraftment. RESULTS: A total of 130 patients were included of whom 78 (60%) were males. The median age at transplant was 36 (range: 2–65) years, 44 (33%) presented ABO incompatibility, 75 (58%) had acute leukemia, 111 (85%) had a related donor, 100 (77%) received peripheral blood hematopoietic stem cells as graft source and 99 (76%) underwent a myeloablative conditioning regimen. There was no statistically significant association between ABO incompatibility and overall survival, event-free survival, transplant-related mortality, grade II–IV acute graft-versus-host disease, neutrophil or platelet engraftment in multivariate analysis. CONCLUSION: These results show that ABO incompatibility does not seem to influence these parameters in patients undergoing allogeneic hematopoietic stem cell transplantation.
format Online
Article
Text
id pubmed-6371230
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-63712302019-02-21 Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study Júnior, José Alfreu Soares Martinho, Glaucia Helena Macedo, Antonio Vaz de Verçosa, Marisa Ribeiro Nobre, Vandack Teixeira, Gustavo Machado Hematol Transfus Cell Ther Original Article BACKGROUND: ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment. METHODS: This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Patients receiving umbilical cord blood as the stem cell source were excluded from this analysis. The impact of ABO incompatibility was evaluated in respect to overall survival, event-free survival, transplant-related mortality, acute graft-versus-host disease and engraftment. RESULTS: A total of 130 patients were included of whom 78 (60%) were males. The median age at transplant was 36 (range: 2–65) years, 44 (33%) presented ABO incompatibility, 75 (58%) had acute leukemia, 111 (85%) had a related donor, 100 (77%) received peripheral blood hematopoietic stem cells as graft source and 99 (76%) underwent a myeloablative conditioning regimen. There was no statistically significant association between ABO incompatibility and overall survival, event-free survival, transplant-related mortality, grade II–IV acute graft-versus-host disease, neutrophil or platelet engraftment in multivariate analysis. CONCLUSION: These results show that ABO incompatibility does not seem to influence these parameters in patients undergoing allogeneic hematopoietic stem cell transplantation. Sociedade Brasileira de Hematologia e Hemoterapia 2019 2018-07-10 /pmc/articles/PMC6371230/ /pubmed/30793098 http://dx.doi.org/10.1016/j.htct.2018.05.007 Text en © 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Júnior, José Alfreu Soares
Martinho, Glaucia Helena
Macedo, Antonio Vaz de
Verçosa, Marisa Ribeiro
Nobre, Vandack
Teixeira, Gustavo Machado
Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_full Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_fullStr Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_full_unstemmed Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_short Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_sort assessing the impact of abo incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371230/
https://www.ncbi.nlm.nih.gov/pubmed/30793098
http://dx.doi.org/10.1016/j.htct.2018.05.007
work_keys_str_mv AT juniorjosealfreusoares assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT martinhoglauciahelena assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT macedoantoniovazde assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT vercosamarisaribeiro assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT nobrevandack assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT teixeiragustavomachado assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy